BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23253862)

  • 1. The incidence of co-existing BCR-ABL1 and JAK2 V617F rearrangements: implications for molecular diagnostics.
    McCarron SL; Haslam K; Crampe M; Langabeer SE
    Lab Hematol; 2012 Dec; 18(4):20-1. PubMed ID: 23253862
    [No Abstract]   [Full Text] [Related]  

  • 2. BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.
    Tokunaga M; Ezoe S; Tanaka H; Satoh Y; Fukushima K; Matsui K; Shibata M; Tanimura A; Oritani K; Matsumura I; Kanakura Y
    J Biol Chem; 2010 Oct; 285(41):31774-82. PubMed ID: 20663870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2-V617F and BCR-ABL--double jeopardy?
    Krämer A
    Leuk Res; 2008 Oct; 32(10):1489-90. PubMed ID: 18439674
    [No Abstract]   [Full Text] [Related]  

  • 4. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
    Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
    Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of double positive myeloproliferative neoplasm: A diagnostic and therapeutic challenge.
    Shaikh AB; Aribandi A; Gupta A; Subramanian SK; Goyal M
    Indian J Pathol Microbiol; 2021; 64(4):820-823. PubMed ID: 34673614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
    Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A
    Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis.
    Kronenwett R; Gräf T; Neumann F; Pechtel S; Steidl U; Diaz-Blanco E; Haas R
    Leuk Res; 2006 Oct; 30(10):1323-4. PubMed ID: 16442619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into JAK2-V617F mutation in CML.
    Bocchia M; Vannucchi AM; Gozzetti A; Guglielmelli P; Poli G; Crupi R; Defina M; Bosi A; Francesco L
    Lancet Oncol; 2007 Oct; 8(10):864-6. PubMed ID: 17913657
    [No Abstract]   [Full Text] [Related]  

  • 9. Insights into JAK2-V617F mutation in CML.
    Büsche G; Hussein K; Bock O; Kreipe H
    Lancet Oncol; 2007 Oct; 8(10):863-4. PubMed ID: 17913656
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical and laboratory relevance of JAK2 V617F and BCR-ABL co-existence in Philadelphia positive CML patients.
    Ahmad N; Qayum S; Jameel A; Ali A; Siraj S; Ali J; Yousafzai YM
    Pak J Pharm Sci; 2021 Nov; 34(6(Supplementary)):2289-2295. PubMed ID: 35039265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.
    Xu W; Chen B; Tong X
    Int J Hematol; 2014 Jan; 99(1):87-90. PubMed ID: 24293258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
    Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
    Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.
    Hussein K; Bock O; Theophile K; Seegers A; Arps H; Basten O; Grips KH; Franz-Werner J; Büsche G; Kreipe H
    Leukemia; 2008 May; 22(5):1059-62. PubMed ID: 17972958
    [No Abstract]   [Full Text] [Related]  

  • 14. [BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation].
    Amemiya A; Ito Y; Ishibashi Y; Saito Y; Katagiri S; Suguro T; Asano M; Yoshizawa S; Akahane D; Tanaka Y; Fujimoto H; Okabe S; Gotoh M; Tauchi T; Ohyashiki K
    Rinsho Ketsueki; 2017; 58(4):298-302. PubMed ID: 28484156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipocalin-2 is associated with modulation of disease phenotype in a patient with concurrent JAK2-V617F and BCR-ABL mutation.
    Nadarajan VS; Ang CH; Bee PC
    Eur J Haematol; 2012 Feb; 88(2):175-8. PubMed ID: 21950422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis.
    Jallades L; Hayette S; Tigaud I; Johnston A; Coiffier B; Magaud JP; Ffrench M
    Leuk Res; 2008 Oct; 32(10):1608-10. PubMed ID: 18448166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.
    de Conchon MRM; Costa JL; Novaes MMY; Dorlhiac-Llacer PE; de Alencar Fischer Chamone D; Bendit I
    Int J Hematol; 2008 Sep; 88(2):243-245. PubMed ID: 18626727
    [No Abstract]   [Full Text] [Related]  

  • 18. Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.
    Luque Paz D; Ianotto JC; Chauveau A; Guibourg B; Lecucq L; Lippert E; Ugo V
    Ann Hematol; 2016 Jan; 95(2):349-50. PubMed ID: 26459144
    [No Abstract]   [Full Text] [Related]  

  • 19. Mutational analysis in chronic myeloid leukemia: when and what to do?
    Branford S; Hughes TP
    Curr Opin Hematol; 2011 Mar; 18(2):111-6. PubMed ID: 21245758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.
    Caocci G; Atzeni S; Orrù N; Littera R; Culurgioni F; Marongiu F; La Nasa G
    Leuk Res; 2010 Jan; 34(1):e27-9. PubMed ID: 19748671
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.